WALTHAM, Mass. – BostonGene, a leader in artificial intelligence-powered solutions for drug discovery and oncology, has been named the “AI-based Drug Discovery Solution of the Year” in the 2025 AI Breakthrough Awards. The prestigious honor highlights the company’s innovative use of AI to accelerate and refine precision cancer treatment and drug development.
Now in its eighth year, the AI Breakthrough Awards program recognizes top-performing companies and technologies in the global artificial intelligence space. This year’s competition saw over 5,000 nominations from more than 20 countries.
BostonGene was recognized for its AI-driven platform that integrates digital pathology with genomic, transcriptomic, and clinical data to generate detailed biological signatures. These signatures are used to identify therapeutic targets and improve patient stratification in clinical trials, enhancing the precision and speed of drug development.
“BostonGene’s AI platform delivers powerful, accurate and reproducible biological signatures that represent an enhanced approach to drug development — bringing precision oncology closer to clinical reality,” said Steve Johansson, managing director at AI Breakthrough.
The platform combines whole slide image analysis with molecular and clinical datasets, enabling a comprehensive view of each patient’s cancer. This multimodal approach is designed to deliver deeper insights into disease mechanisms and treatment responses.
Ferran Prat, PhD, JD, Chief Commercial Officer at BostonGene, emphasized the company’s collaborative approach. “Through our strategic collaborations with leading cancer centers and pharmaceutical companies, we are integrating advanced technology like AI into oncology care,” Prat said. “We’re grateful to AI Breakthrough for this award and remain focused on revolutionizing personalized cancer treatment, expediting drug development, and improving patient outcomes.”
BostonGene’s recognition comes amid a global surge in AI innovation, with the awards program also highlighting major advancements across generative AI, computer vision, robotics, and natural language processing.
